Head-to-head comparison: Key clinical facts
This comparison summarizes the primary differences according to the British National Formulary (BNF) and UK clinical prescribing guidelines:
| Feature | Pregabalin | Gabapentin |
|---|---|---|
| UK Licensed Indications | Peripheral & central neuropathic pain, GAD (anxiety), adjunctive focal epilepsy | Peripheral neuropathic pain, adjunctive focal epilepsy. (NOT licensed for anxiety) |
| Typical Daily Dose Range | 150mg to 600mg per day | 900mg to 3,600mg per day |
| Relative Potency Ratio | ~ 6x more potent by weight (e.g. 50mg) | Baseline (e.g. 300mg) |
| Dosing Schedule | Usually 2 times daily (sometimes 3) | Strictly 3 times daily |
| Oral Bioavailability | ≥ 90% (linear & predictable): Doubling the dose doubles the blood level | 33% to 60% (saturable & non-linear): Bioavailability drops sharply as the dose increases |
| Time to Peak Level (Tmax) | ~ 1 hour (rapid absorption) | ~ 2 to 3 hours |
| UK Controlled Drug Status | Class C, Schedule 3 CD (No Register) | Class C, Schedule 3 CD (No Register) |
| Renal Elimination | > 98% unchanged by kidneys | 100% unchanged by kidneys |
Absorption and bioavailability: The major clinical difference
The most important pharmacological difference between the two drugs lies in how they are absorbed through the intestinal wall:
Gabapentin’s saturable absorption
Gabapentin relies exclusively on a specialized transport system in the gut called the L-type amino acid transporter (LAT1). These transport sites are limited in capacity.
When you take a low dose of gabapentin (such as 300mg), roughly 60% is absorbed into the bloodstream. However, when the dose is increased to 1,200mg or 3,600mg daily, the transporters become saturated. Consequently, bioavailability drops to as low as 33%. This makes clinical response unpredictable: doubling the oral dose does not double the amount of medicine reaching the brain.
Pregabalin’s linear absorption
Pregabalin also uses the LAT1 transporter, but it has much higher affinity and is absorbed through passive and active mechanisms that do not saturate at therapeutic doses. Its bioavailability remains steady at ≥90% across the entire licensed dose range (150mg to 600mg). If a doctor doubles your dose from 75mg twice daily to 150mg twice daily, the blood concentration doubles predictably.
Approximate dose equivalence table
When pain specialists or neurologists convert patients from gabapentin to Pregabalin, they use approximate clinical equivalence guidelines (roughly a 1:6 ratio):
| Gabapentin Daily Dose (Three Times Daily) | Approximate Equivalent Pregabalin Daily Dose (Divided) |
|---|---|
| 300mg daily (100mg three times a day) | 50mg daily (25mg twice a day) |
| 900mg daily (300mg three times a day) | 150mg daily (75mg twice a day) |
| 1,800mg daily (600mg three times a day) | 300mg daily (150mg twice a day) |
| 2,400mg daily (800mg three times a day) | 400mg–450mg daily (divided) |
| 3,600mg daily (1,200mg three times a day) | 600mg daily (300mg twice a day) |
Side effect differences
Because both medicines belong to the same pharmacological class, their adverse effect profiles overlap considerably. Both medications commonly cause:
- Dizziness, lightheadedness, and ataxia (loss of balance)
- Drowsiness, daytime somnolence, and tiredness
- Peripheral oedema (swollen feet and ankles)
- Increased appetite and weight gain
- Difficulty concentrating and short-term memory lapses
However, clinical experience shows that individual patient tolerability varies. Some patients who experience severe brain fog or nausea on gabapentin tolerate Pregabalin comfortably, and vice versa.
How clinicians switch between the two medicines
There are two recognized clinical methods for switching:
- Direct (overnight) switch: In patients taking low-to-moderate doses who need a rapid transition, the doctor may instruct stopping gabapentin at night and initiating the equivalent Pregabalin dose the following morning.
- Cross-tapering: In patients taking high doses or who are sensitive to withdrawal, the doctor gradually tapers gabapentin down over 1 to 2 weeks while simultaneously titrating Pregabalin upward.
Clinical sources and references
- BNF: Neuropathic pain treatment summary and gabapentinoid comparison
- British Journal of Clinical Pharmacology: Clinical pharmacokinetics of pregabalin and gabapentin
- NICE CG173: Pharmacological management of neuropathic pain
- Home Office: Reclassification of Pregabalin and Gabapentin as Schedule 3 Controlled Drugs